Safety and efficacy of anti-tumor necrosis factors &alpha; in patients with psoriasis and chronic hepatitis C

doi:10.12998/wjcc.v4.i2.49

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8143)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

604

WORD

485

HTML

3888

Figures (1-6)

281

Sum=5258

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1108

Download

1777

Sum=2885

Feb 16, 2016 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Feb 16, 2016; 4(2): 49-55
Published online Feb 16, 2016. doi: 10.12998/wjcc.v4.i2.49

Full Size Figure Download Figure

Figure 1 Basaline features: Psoriasis Area and Severity Index score 11. 5, starting dose of cyclosporine 4 mg/kg per day.

Citation: Salvi M, Macaluso L, Luci C, Mattozzi C, Paolino G, Aprea Y, Calvieri S, Richetta AG. Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C. World J Clin Cases 2016; 4(2): 49-55
URL: https://www.wjgnet.com/2307-8960/full/v4/i2/49.htm
DOI: https://dx.doi.org/10.12998/wjcc.v4.i2.49